Searched for
LUPIN LIMITED NEWS
Lupin launches generic Sugammadex injection in USLupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Admini...- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Lupin shares gain 2% after USFDA approval for HIV drugLupin's shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovi...
- Lupin shares rise nearly 3% on launch of Rivaroxaban Tablets USP, in the USLupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over the last six mo...
- Lupin season 4 release date on Netflix: Is Lupin part 4 happening?Lupin season 4 will be releasing on Netflix even though the production for the same is yet to commence, according to a report.
- Lupin shares in focus as USFDA inspection at Somerset facility concludes with no observationsEarlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 manufacturing facili...
- Stocks in news: RIL, Bharti Airtel, Vedanta, Tata Power, LupinIndian benchmark indices plummeted almost 3% on Monday amid global market shocks and concerns over a US economy slowdown. RIL, Bharti Airte...
- Stocks in news: Adani Ports, Cipla, Prestige Estates, MCX, LupinPositive growth in domestic markets for the third consecutive week with a focus on Adani Ports, Cipla, Prestige Estates, MCX, Lupin. Update...
- Stocks in news: PB Fintech, Dr Reddy's, HPCL, Godrej Consumer, LTIMindtreePharma company Lupin on Monday reported 52% year-on-year growth in its consolidated net profit at Rs 368 crore for the quarter ended March ...
- Pharma stock that Jhunjhunwala exited in Q2 is now buzzing. Here's what analysts sayAce investor Rakesh Jhunjhunwala probably exited this counter in the second quarter, as his name was not among the shareholders holding ove...
- Licence to sell cancer drug biggest opportunity for Dr Reddy’s in US market: Nirmal Bang‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’
- Lupin trades above Rs 1,000 for the first time since Nov 2017The pharma major last week reported a 64.72 per cent decline in its consolidated net profit to Rs 106.90 crore for the quarter to June 2020...
- Lupin shares tumble over 6% on earnings disappointmentOn the NSE, it tumbled 6.24 per cent to Rs 877.80.
- Lupin Q1 net profit drops 65% to Rs 107 croreDrug firm Lupin has reported a 64.72 per cent decline in its consolidated net profit to Rs 106.90 crore for the quarter to June 2020, hit b...
- Outlook 2019: Pharma looks medically fit for double-digit growth after years of sufferingClearance in 483 observations indicates increased regulatory compliance by the companies.
- India isn’t cheap versus other Asian markets: Adrian Lim, Aberdeen Asset Management"The MSCI India Index is trading at around 22 times earnings, compared to 13.5 times for the MSCI Asia Pacific ex-Japan benchmark."
- Put trailing stop losses in place for midcap stocks: Guarang ShahWhen the lesser-known names start reacting on the negative side, then there would be a bit of deeper cut, says Shah in an interview with ET...
- Lupin stock vaults to 52-week high on generic launch of Novartis' DiovanThe stock has gained 25% in the last one year – and has been one of the best performing stocks among the frontline pharma companies.
- Lupin mulls sale of its Indian unit that markets drugsLupin Limited, the world's largest maker of drugs to fight tuberculosis, is considering selling its unit that markets drugs in India, said ...
Load More
